Focus Partners Wealth Purchases New Position in Organon & Co. (NYSE:OGN)

Focus Partners Wealth purchased a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 41,950 shares of the company's stock, valued at approximately $627,000.

Other institutional investors also recently modified their holdings of the company. Barclays PLC lifted its stake in shares of Organon & Co. by 238.0% during the 3rd quarter. Barclays PLC now owns 119,483 shares of the company's stock valued at $2,285,000 after buying an additional 84,136 shares in the last quarter. Hsbc Holdings PLC increased its holdings in Organon & Co. by 13.9% during the 4th quarter. Hsbc Holdings PLC now owns 13,922 shares of the company's stock worth $208,000 after acquiring an additional 1,703 shares during the period. Robeco Institutional Asset Management B.V. bought a new stake in Organon & Co. during the 4th quarter worth approximately $2,263,000. Sippican Capital Advisors increased its holdings in Organon & Co. by 138.7% during the 4th quarter. Sippican Capital Advisors now owns 36,352 shares of the company's stock worth $542,000 after acquiring an additional 21,122 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in Organon & Co. by 28.6% during the 4th quarter. Wells Fargo & Company MN now owns 262,746 shares of the company's stock worth $3,920,000 after acquiring an additional 58,378 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Organon & Co. news, CFO Matthew M. Walsh acquired 11,400 shares of the business's stock in a transaction dated Monday, May 5th. The stock was bought at an average price of $8.82 per share, with a total value of $100,548.00. Following the purchase, the chief financial officer now owns 144,484 shares of the company's stock, valued at approximately $1,274,348.88. This trade represents a 8.57% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel Karp acquired 3,500 shares of the business's stock in a transaction dated Tuesday, May 6th. The stock was acquired at an average cost of $8.24 per share, with a total value of $28,840.00. Following the purchase, the vice president now directly owns 46,669 shares in the company, valued at $384,552.56. This represents a 8.11% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 102,345 shares of company stock valued at $902,430. Corporate insiders own 1.96% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on OGN. Piper Sandler decreased their target price on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Morgan Stanley decreased their target price on shares of Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Barclays decreased their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Finally, Evercore ISI lowered shares of Organon & Co. from an "outperform" rating to an "inline" rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $18.00.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $9.00 on Tuesday. The company's fifty day moving average price is $12.09 and its 200-day moving average price is $14.24. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of 2.70, a PEG ratio of 0.90 and a beta of 0.75. Organon & Co. has a one year low of $8.01 and a one year high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.13. The firm had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.53 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business's revenue for the quarter was down 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.22 EPS. On average, equities research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Monday, May 12th will be paid a $0.02 dividend. The ex-dividend date of this dividend is Monday, May 12th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.89%. Organon & Co.'s dividend payout ratio (DPR) is 2.78%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.